Abstract
Background
The regulatory-approved R21/Matrix-MTM malaria vaccine is the second of its kind and the product of more than 30 years of research by the Jenner Institute, University of Oxford, UK, and its partners.
Methods
We conducted unsystematic online search for relevant literature and the retrieved materials were then critically studied and synthesised to provide deeper insight into the development, components, clinical trial results and limitations of the R21-Matrix-MTM malaria vaccine.
Results
In clinical trials, the R21-Matrix-MTM elicited the highest levels of antibodies at a 10 µg dose per injection compared to other tested doses, reaching an efficacy of 77%. Researchers administered the vaccine intramuscularly as a three-dose primary series, with intervals of four weeks each, followed by a booster 12 months after the third dose was completed. The elicited antibodies target the antigen NANP, which is a repeated amino acid sequence asparagine-alanine-asparagine-proline (NANP) embedded within the circumsporozoite protein (CSP) of Plasmodium falciparum.
Conclusion
The R21/Matrix-MTM vaccine is a revolutionary intervention to prevent malaria in children between the ages of 3 and 5. We strongly encourage malaria vaccines for the adult group to overcome inequality and form a more formidable force for the eradication of malaria globally. There seem to be less excitement about the vaccine, possibly due to enduring familiarity with malaria and availability of existing interventions, this is likely to interfere with the vaccine uptake and/or adherence to the required doses. There’s needs for public awareness in targeted areas.
Keywords:
Antibodies, malaria vaccine, NANP, Plasmodium falciparum, R21, Matrix-MReferences
World malaria report 2023. Geneza: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.
University of oxford. R21/Matrix-MTM malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana. 2023 Apr 13 [cited 2024 Feb 18]. https://www.ox.ac.uk/news/2023-04-13-r21matrix-m-malaria-vaccine-developed-university-oxford-receives-regulatory
RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. The Lancet. 2015;386(9988):31-45.
Parums DV. Editorial: Current Status of Two Adjuvanted Malaria Vaccines and the World Health Organization (WHO) Strategy to Eradicate Malaria by 2030. Medical Science Monitor. 2023;29.
Genton B. R21/Matrix-MTM malaria vaccine: a new tool to achieve WHO’s goal to eliminate malaria in 30 countries by 2030? J Travel Med. 2023;30(8).
Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature. 1967; 216(5111), 160–162.
Ballou WR, Cahill CP. Two decades of commitment to malaria vaccine development: GlaxoSmithKline Biologicals. The American journal of tropical medicine and hygiene. 2007;77(6 Suppl), 289–295.
Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. The American journal of the medical sciences. 1973;266(3), 169–177.
Ballou WR, Hoffman SL., Sherwood JA, et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet (London, England). 1987;1(8545), 1277–1281
Hoffman SL., Goh LM, Luke TC, et al. (2002). Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. The Journal of infectious diseases. 2002;185(8), 1155–1164.
El-Moamly AA, El-Sweify MA. Malaria vaccines: the 60-year journey of hope and final success—lessons learned and future prospects. Trop Med Health. 2023;51(1):29.
Goodman AL, Draper SJ. Blood-stage malaria vaccines - recent progress and future challenges. Annals of tropical medicine and parasitology. 2010;104(3), 189–211.
Sirima SB, Cousens S, Druilhe P. Protection against malaria by MSP3 candidate vaccine. The New England journal of medicine. 2011;365(11), 1062–1064.
Thera MA, Doumbo OK, Coulibaly D, et al. A field trial to assess a blood-stage malaria vaccine. The New England journal of medicine. 2011;365(11), 1004–1013.
Payne RO, Milne K., Elias SC, et al. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. The Journal of infectious diseases. 2016;213(11), 1743–1751.
Collins KA, Snaith R, Cottingham MG, Gilbert SC, Hill AVS. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci Rep. 2017;7.
Datoo MS, Natama HM, Somé A, et al. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years’ follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. Lancet Infect Dis. 2022;22(12):1728-1736.
Mukhopadhyay E, Brod F, Angell-Manning P, et al. Production of a high purity, C‐tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions. Biotechnol Bioeng. 2022;119(10):2784-2793.
Cox RJ, Pedersen G, Madhun AS, et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix MTM adjuvant in a phase I clinical trial. Vaccine. 2011;29(45):8049-8059.
Portnoff AD, Patel N, Massare MJ, et al. Influenza Hemagglutinin Nanoparticle Vaccine Elicits Broadly Neutralizing Antibodies against Structurally Distinct Domains of H3N2 HA. Vaccines (Basel). 2020;8(1):99.
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. New England Journal of Medicine. 2020;383(24):2320-2332.
Stertman L, Palm AE, Zarnegar B, et al. The Matrix-MTM adjuvant: A critical component of vaccines for the 21st century. Hum Vaccin Immunother. 2023;19(1).
Duffy PE, Sahu T, Akue A, Milman N, Anderson C. Pre-erythrocytic malaria vaccines: identifying the targets. Expert Rev Vaccines. 2012;11(10):1261-1280.
Coppi A, Natarajan R, Pradel G, et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. Journal of Experimental Medicine. 2011;208(2):341-356.
Rathore D, Nagarkatti R, Jani D, et al. An Immunologically Cryptic Epitope of Plasmodium falciparum Circumsporozoite Protein Facilitates Liver Cell Recognition and Induces Protective Antibodies That Block Liver Cell Invasion. Journal of Biological Chemistry. 2005;280(21):20524-20529.
Gavi vaccine alliance. Gavi’s impact in Africa since 2000. 2024 May 2 [cited 2024 May 11]. https://www.gavi.org/vaccineswork/gavi-impact-africa-2000
Datoo MS, Natama MH, Somé A, et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. The Lancet. 2021;397(10287):1809-1818.
Tsoumani ME, Voyiatzaki C, Efstathiou A. Malaria Vaccines: From the Past towards the mRNA Vaccine Era. Vaccines (Basel). 2023;11(9):1452.
Datoo MS, Dicko A, Tinto H, Ouédraogo JB, Hamaluba M, Olotu A, et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. The Lancet. 2024;403(10426):533-544.
Schmit N, Topazian HM, Natama HM, et al. The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study. Lancet Infect Dis. 2024;24(5):465-475.
Vanderberg JP, Sidjanski S. Delayed Migration of Plasmodium Sporozoites from the Mosquito Bite Site to the Blood. Am J Trop Med Hyg. 1997;57(4):426-429.
Sinnis P, Coppi A. A long and winding road: The Plasmodium sporozoite’s journey in the mammalian host. Parasitol Int. 2007;56(3):171-178.
Baer K, Klotz C, Kappe SHI, Schnieder T, Frevert U. Release of Hepatic Plasmodium yoelii Merozoites into the Pulmonary Microvasculature. PLoS Pathog. 2007;3(11):e171.
Medica DL, Sinnis P. Quantitative Dynamics of Plasmodium yoelii Sporozoite Transmission by Infected Anopheline Mosquitoes. Infect Immun. 2005;73(7):4363-4369.
Kebaier C, Voza T, Vanderberg J. Kinetics of Mosquito-Injected Plasmodium Sporozoites in Mice: Fewer Sporozoites Are Injected into Sporozoite-Immunized Mice. PLoS Pathog. 2009;5(4):e1000399.
Hodgson SH, Ewer KJ, Bliss CM, et al. Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. Journal of Infectious Diseases. 2015;211(7):1076-1086.
O’Hara GA, Duncan CJA, Ewer KJ, et al. Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. J Infect Dis. 2012;205(5):772-781.
Gordon DM, McGovern TW, Krzych U, et al. Safety, Immunogenicity, and Efficacy of a Recombinantly Produced Plasmodium falciparum Circumsporozoite Protein-Hepatitis B Surface Antigen Subunit Vaccine. Journal of Infectious Diseases. 1995;171(6):1576-1585.
Heppner DG Jr, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine. 2005;23(17-18):2243-2250.
Laurens MB. RTS,S/AS01 vaccine (MosquirixTM): an overview. Hum Vaccin Immunother. 2020;16(3):480-489.
Venkatraman N, Tiono AB, Bowyer G, et al. Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers. MedRxiv. 2019:19009282.
Sang S, Datoo MS, Otieno E, et al. Safety and immunogenicity of varied doses of R21/Matrix-MTM vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya. Wellcome Open Res. 2023;8:450.
Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 2009;30(1):23-32.
Reinke S, Pantazi E, Chappell GR, et al. Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms. Cell Rep Med. 2023 Nov 21;4(11):101245
Didierlaurent AM, Collignon C, Bourguignon P, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol. 2014;193(4):1920–30.
Magnusson SE, Altenburg AF, Bengtsson KL, Bosman F, de Vries RD, Rimmelzwaan GF, Stertman L. Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res. 2018;66(2):224–33.
den Brok MH, Bull C, Wassink M, et al. Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation. Nat Commun. 2016;7:13324
Venkatraman N, Bowyer G, Edwards NJ, et al. High level efficacy in humans of a next-generation plasmodium falciparum anti-sporozoite vaccine: R21 in Matrix-M™ adjuvant. In: Abstract of the 66th Annual Meeting of the American Society of Tropical Medicine and Hygiene; Baltimore, Maryland USA; 2017 Nov 5-9. Abstract 1911.
Hill A. Clinical Trial Protocol: VAC053 Protocol v5.0. University of Oxford, 2019.
Hill, A. Clinical Trial Protocol: VAC060 Protocol v3.0. University of Oxford, 2019.
RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011;365(20):1863-1875.
How to Cite
License
Copyright (c) 2024 Lipigwe Lauya, Abednego Samuel Dahal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright© by the author(s). Published by the Evidence Journals. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.